About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Active Not RecruitingPhase 1/2

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Phase I/II of Durvalumab (MEDI4736) + Tremelimumab + Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma

NCT03283605•Centre hospitalier de l'Université de Montréal (CHUM)

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Head and Neck Squamous Cell CarcinomaMetastatic Squamous Cell Carcinoma

Interventions

SBRT

Durvalumab

+1 more

Locations

3

Canada

Locations (3)

Cross Cancer Institute

Edmonton, Alberta, Canada

London Regional Cancer Program of the Lawson Health Research Institute

London, Ontario, Canada

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

Key Dates

Start Date

July 17, 2018

Primary Completion Date

July 31, 2024

Completion Date

December 31, 2024

Last Updated

June 28, 2024

Related Studies

RECRUITINGPhase 1

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT05039801

Advanced Endometrial CarcinomaAdvanced Head and Neck Squamous Cell Carcinoma+36 more

RECRUITINGPhase 2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

NCT06980038

Head and Neck Squamous Cell CarcinomaHypopharyngeal Squamous Cell Carcinoma+20 more

RECRUITINGPhase 1

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

NCT06806852

Head and Neck Squamous Cell Carcinoma

RECRUITINGPhase 1

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

NCT05526924

Head and Neck CancerHead and Neck Squamous Cell Carcinoma+3 more

RECRUITINGPhase 2

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

NCT05977907

Head and Neck Squamous Cell Carcinoma

RECRUITINGPhase 2

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

NCT02734537

Head and Neck Squamous Cell CarcinomaHypopharyngeal Squamous Cell Carcinoma+14 more

View all related studies

Sponsors

Lead Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Collaborators

AstraZeneca

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 28, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions